What is the safest way to discontinue mexiletine and sotalol (anti-arrhythmic medications) in a patient with a history of arrhythmias?

How to Discontinue Mexiletine and Sotalol

Sotalol Discontinuation

Sotalol should be gradually tapered over 1-2 weeks rather than stopped abruptly, with careful monitoring for rebound arrhythmias and unmasking of latent coronary insufficiency, particularly in patients with ischemic heart disease. 1

Critical Warnings for Sotalol Withdrawal

• Abrupt discontinuation can precipitate exacerbation of angina pectoris, arrhythmias, myocardial infarction, and sudden death due to hypersensitivity to catecholamines that develops during chronic beta-blocker therapy 1
• Patients must be warned against interrupting or discontinuing therapy without physician supervision 1
• This risk is particularly high in patients with ischemic heart disease, where abrupt cessation may unmask latent coronary insufficiency 1

Tapering Protocol for Sotalol

• Reduce dosage gradually over 1-2 weeks while monitoring closely for signs of arrhythmia recurrence or cardiac ischemia 1
• Consider temporary use of an alternate beta-blocker during the taper if the patient has significant coronary artery disease 1
• If angina or acute coronary insufficiency develops during tapering, institute appropriate anti-ischemic therapy immediately 1

Monitoring During Sotalol Discontinuation

• Monitor for bradycardia rebound (tachycardia), new or worsening arrhythmias, and chest pain 1
• Patients with arrhythmias may have unrecognized coronary artery disease, making careful monitoring essential 1
• Watch for signs of heart failure exacerbation, as withdrawal of beta-blockade removes sympathetic support 1

---

Mexiletine Discontinuation

Mexiletine can generally be discontinued without a mandatory taper, as there is no evidence of significant withdrawal syndrome or rebound arrhythmias comparable to beta-blockers, though monitoring for arrhythmia recurrence is prudent.

Discontinuation Approach for Mexiletine

• Unlike sotalol, mexiletine (a class Ib sodium channel blocker) does not have the same withdrawal risks associated with beta-blockade 2, 3
• Discontinuation can be abrupt if clinically necessary, though gradual reduction over several days may be considered for patient comfort 2
• The primary concern is return of the underlying ventricular arrhythmia rather than a withdrawal syndrome 4, 5

Monitoring After Mexiletine Discontinuation

• Monitor for recurrence of ventricular ectopy or tachyarrhythmias that were previously suppressed 4, 6
• Patients with life-threatening arrhythmias (ventricular tachycardia/fibrillation) require closer monitoring than those treated for symptomatic PVCs 5, 6
• Consider continuous ECG monitoring for 24-48 hours in high-risk patients (those with sustained VT or VF history) 6

---

Special Considerations When Discontinuing Both Drugs

Sequential vs. Simultaneous Discontinuation

• When discontinuing both medications, taper sotalol first over 1-2 weeks while maintaining mexiletine, then discontinue mexiletine after sotalol withdrawal is complete 1
• This approach minimizes the risk of beta-blocker withdrawal syndrome while maintaining some antiarrhythmic coverage 1

High-Risk Patient Populations

• Patients with ischemic heart disease require the most cautious sotalol taper with consideration of alternative beta-blocker bridging 1
• Patients with history of sustained ventricular tachycardia or fibrillation need continuous monitoring when stopping mexiletine 5, 6
• Those with congestive heart failure may experience worsening symptoms during sotalol withdrawal due to loss of rate control 1

Common Pitfalls to Avoid

• Never allow patients to abruptly stop sotalol on their own (e.g., running out of medication, non-compliance) without medical supervision 1
• Do not discontinue sotalol rapidly in patients with unrecognized coronary disease, as arrhythmias may mask underlying ischemia 1
• Avoid stopping mexiletine without a plan for alternative arrhythmia management in patients with refractory ventricular arrhythmias 6

Post-Discontinuation Follow-up

• Schedule follow-up within 1-2 weeks after complete discontinuation to assess for arrhythmia recurrence 4
• Obtain ECG and assess symptoms at follow-up visit 1
• For patients with implantable cardioverter-defibrillators, review device interrogation for any arrhythmic events during and after discontinuation 6